PureTech Health (PRTC) Expected to Post Quarterly Earnings on Thursday

PureTech Health (NASDAQ:PRTC) will likely be announcing its H1 2026 resultson Thursday, August 27th. Analysts expect the company to announce earnings of ($1.16) per share and revenue of $24.80 million for the quarter. Parties can check the company’s upcoming H1 2026 earning summary page for the latest details on the call scheduled for Friday, September 4, 2026 at 3:00 AM ET.

PureTech Health Price Performance

NASDAQ:PRTC opened at $17.42 on Tuesday. PureTech Health has a 52-week low of $14.50 and a 52-week high of $19.92. The stock has a fifty day moving average of $17.42 and a 200 day moving average of $17.25.

Institutional Inflows and Outflows

An institutional investor recently raised its position in PureTech Health stock. Pentwater Capital Management LP raised its position in shares of PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) by 50.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 75,000 shares of the company’s stock after purchasing an additional 25,000 shares during the period. Pentwater Capital Management LP owned approximately 0.31% of PureTech Health worth $1,388,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.04% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings cut PureTech Health from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 18th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About PureTech Health

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.